Nanobiotix (ENXTPA:NANO) has drawn investor attention after announcing a royalty-based financing agreement with HealthCare Royalty, unlocking up to $71 million in capital. This move strengthens its financial footing and supports the advancement of future nanotherapeutic products.

See our latest analysis for Nanobiotix.

Momentum has shifted dramatically for Nanobiotix, with the share price surging 502.86% year-to-date and an impressive 173.16% gain over the last 90 days. This follows the recent financing agreement and a series of upcoming healthcare conference appearances. The 1-year total shareholder return stands at 395.19%, reinforcing the view that investor optimism around the company’s funding and growth prospects continues to accelerate.

If the pace at Nanobiotix has sparked your interest, it could be the perfect moment to broaden your search and discover See the full list for free.

After such an extraordinary run, the real question is whether Nanobiotix is still undervalued or if the current share price already reflects the company’s anticipated growth. Does this mark a genuine buying opportunity, or is the market a step ahead?

Nanobiotix trades at a price-to-book ratio of -13x, a figure that stands out sharply against both peer and industry averages. The last close price of €18.52, when paired with this negative multiple, highlights a disconnect created by the company’s negative equity position.

The price-to-book ratio compares a company's market price to its book value per share. It is often used to assess asset-heavy businesses or those with fluctuating profits. For Nanobiotix, the negative ratio reflects that total liabilities exceed total assets. This situation is uncommon and signals deeper capital structure challenges in biotech firms pursuing growth before profitability.

Relative to both the peer average (4.4x) and the French Biotechs industry average (2.6x), Nanobiotix's price-to-book ratio underscores just how far the business is at odds with traditional valuation anchors. The market is clearly focused on future prospects rather than book value. If book value rebounds, multiples could move rapidly.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Book Ratio of -13x (ABOUT RIGHT)

However, persistent negative net income and reliance on future funding rounds could challenge the company’s ability to sustain its recent momentum.

Find out about the key risks to this Nanobiotix narrative.

Feel free to dive into the numbers yourself and develop your own take on Nanobiotix's story. Craft your personal perspective in just minutes. Do it your way

A great starting point for your Nanobiotix research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Smart investors know that focusing on a single opportunity can mean missing out on the next breakout. Use Simply Wall Street’s powerful screeners to uncover stocks with explosive potential, unique technology, or standout income prospects.

Capture growth trends by jumping into these 27 AI penny stocks, which are set to transform entire industries through artificial intelligence and machine learning advancements.

Target steady income streams with 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 14 dividend stocks with yields > 3%, offering attractive yields and robust financial health.

Get ahead of the curve with these 27 quantum computing stocks, driven by innovation in quantum computing and positioned for long-term market impact.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NANO.PA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com